Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProAgio and Gemcitabine in Metastatic Triple Negative Breast Cancer
NCT06460298Phase 2Recruiting
- Sponsor
- ProDa BioTech
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of proagio in triple-negative breast cancer (TNBC) (2 arms), sponsored by ProDa BioTech. Primary endpoints: Part 1 (Dose Escalation) at 2 years and Part 2 (Dose Expansion) at 2 years. Started Aug 2024; status: recruiting.
02
Drugs
proagio
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06460298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06460298.